SANOFI news, videos and press releases - Page 3
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
- Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
- Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
- Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
- Sanofi: Information concerning the total number of voting rights and shares - July 2023
- Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
- Press release: Online availability of Sanofi’s half-year financial report for 2023
- Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
- Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
- Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
- Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
- Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
- Sanofi: Information concerning the total number of voting rights and shares – April 2023
- Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
- Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
- Sanofi: Information concerning the total number of voting rights and shares - March 2023
- Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
- Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
- Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
- Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
- Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
- ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
- Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
- Sanofi: Information concerning the total number of voting rights and shares – January 2023
- Sanofi: Information concerning the total number of voting rights and shares – December 2022
- Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
- Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
- Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
- Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules
- Form 8.3 - The Vanguard Group, Inc.: Sanofi
